Clinical trials: Patient With Schizophrenia Spectrum Disorder
Healthy Volunteers, Schizophrenia
Effects of Ketamine and Risperidone on Cognition
The primary objective of this study is: To determine the effects of ketamine, which blocks the ion-channel gated by the NMDA receptor, on performance of cognitive tasks and the extent to which these effects can be reversed by the…
- Trial name
- Schiz_2 (NCT01140620)
- Testing
- ketamine, risperidone, saline
- Where
- 3 sites in United Kingdom
- Volunteers
- 87 people, healthy volunteers welcome
- Sponsor
- University of Manchester
Schizophrenia
A Study of RO4917838 in Patients With Sub-optimally Controlled Symptoms of Schizophrenia (NN25307)
This randomized, multi-center, double-blind, parallel-group, placebo-controlled study will evaluate the efficacy and safety of RO4917838 in patients with sub-optimally controlled symptoms of schizophrenia.
- Trial name
- NCT01235520
- Testing
- RO4917838
- Where
- 121 sites in United States, Argentina and 12 more
- Volunteers
- 595 people
- Sponsor
- Hoffmann-La Roche
Schizophrenia
Open-label Study to Compare Hospitalization Rates of Schizophrenic Patients Treated With Oral Antipsychotics Versus IM Depot Aripiprazole
The purpose of this study is to compare retrospective hospitalization rates of schizophrenic patients treated with oral antipsychotics to prospective hospitalization rates of these patients treated with IM depot aripiprazole.
- Trial name
- ARRIVE- EU (NCT01509053)
- Testing
- Aripiprazole (Abilify®) IM Depot Injection, Oral aripiprazole
- Where
- 10 sites in Belgium, Bulgaria and 1 more
- Volunteers
- 30 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Schizophrenia, Drug Abuse/Dependency
Influence of Nicotine on Cognitive Function in Schizophrenic Patients With and Without Comorbid Drug Dependence
Background: Individuals with schizophrenia have a significantly higher tendency to develop substance abuse or dependence than the general population.
- Trial name
- NCT01037075
- Where
- 2 sites in United States
- Volunteers
- 82 people, healthy volunteers welcome
- Sponsor
- National Institute on Drug Abuse (NIDA)
Schizophrenia
52-week Open Label Safety-Tolerability Study
Phase 3, open label, multicenter study designed to assess the long term safety and tolerability of LB-102 for the treatment of adult patients with stable schizophrenia
- Trial name
- NOVA3 (NCT07369154)
- Testing
- LB-102
- Where
- 23 sites in United States
- Volunteers
- 900 people
- Sponsor
- LB Pharmaceuticals Inc.
Schizophrenia
A Study of Olanzapine in Patients With Schizophrenia
The primary objectives of the study is to confirm if the efficacy of intramuscular injection (IM) olanzapine 10 milligrams (mg) in patients with an exacerbation of schizophrenia with acute psychotic agitation is greater than…
- Trial name
- NCT00970281
- Testing
- Rapid-Acting Intramuscular Olanzapine
- Where
- 11 sites in Japan
- Volunteers
- 91 people
- Sponsor
- Eli Lilly and Company
Schizophrenia
Safety and Tolerability Study of Drug to Treat Schizophrenia
The purpose of this study is to evaluate the long-term safety of SM-13496 in patients with schizophrenia.
- Trial name
- NCT00044005
- Testing
- Lurasidone 20 mg, Lurasidone 40 mg, Lurasidone 80mg
- Where
- 26 sites in United States
- Volunteers
- 98 people
- Sponsor
- Sumitomo Pharma America, Inc.
Schizophrenia
12 Week Open, Non-Comparative Switch Study Of Oral Ziprazidone In Previously Treated Schizophrenic Patients
There has been evidence that ziprasidone is efficacious in decreasing the magnitude of both positive and negative symptoms of schizophrenia, and also effective in the treatment of depressive symptoms.
- Trial name
- NCT00159757
- Testing
- ziprazidone
- Where
- 8 sites in Hungary
- Volunteers
- 150 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Schizophrenia and Schizoaffective Disorder, Bipolar Disorder (BD)
Survey on the Reproductive and Child-Rearing Situations of Patients With Severe Mental Disorders
Severe mental disorders represent a major public health concern, imposing substantial disease burden and adversely affecting multiple dimensions of patients' lives, while also creating intergenerational impacts on their offspring…
- Trial name
- NCT07005245
- Where
- China
- Volunteers
- 77,145 people
- Sponsor
- Peking University
Parkinson's Disease Psychosis
A Study of the Safety and Efficacy of Pimavanserin (ACP-103) in Patients With Parkinson's Disease Psychosis
This study will evaluate the safety and efficacy of two dose levels of pimavanserin (ACP-103) compared to placebo in patients with Parkinson's disease psychosis.
- Trial name
- NCT00477672
- Testing
- Pimavanserin tartrate (ACP-103)
- Where
- 78 sites in United States, Bulgaria and 5 more
- Volunteers
- 298 people
- Sponsor
- ACADIA Pharmaceuticals Inc.
Schizophrenia
A Follow-on Study of the Long-Term Safety of Aripiprazole in Patients With Chronic Schizophrenia
The primary objective of the study was to determine the safety of aripiprazole administered long-term in doses ranging from 10 to 30 mg per day as a maintenance therapy in subjects with chronic or first episode of schizophrenia.
- Trial name
- NCT02435836
- Testing
- Aripiprazole
- Volunteers
- 631 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Schizophrenia, Cognition Disorders
The Effect of Nicotine on Arousal, Cognition and Social Cognition in Schizophrenic Patients
This study in patients with stable schizophrenia will investigate the effect of nicotine on arousal, cognitive task and social cognition after acute dose administration.
- Trial name
- NCT01186471
- Testing
- A643 (nicotine)
- Volunteers
- 32 people
- Sponsor
- Janssen Pharmaceutica N.V., Belgium
Schizophrenia
The Effects of Varenicline on Cognitive Function in Patients With Schizophrenia
The primary objective of this project is to examine the effects of varenicline treatment used concomitantly with antipsychotic medications, on cognitive dysfunction in people with schizophrenia.
- Trial name
- NCT00523445
- Testing
- Varenicline(Chantix)
- Where
- 5 sites in South Korea
- Volunteers
- 120 people
- Sponsor
- Inje University
Psychotic Disorders
A Study of Taurine in Patients With First-episode Psychosis Receiving Antipsychotic Treatment
The purpose of this study is to determine whether Taurine 4g is effective with antipsychotic medication in the treatment of First Episode Psychosis.Taurine may have an effect on cognition and symptoms.
- Trial name
- NCT00420823
- Testing
- Taurine 4g
- Where
- 2 sites in Australia
- Volunteers
- 121 people
- Sponsor
- Melbourne Health
Major Depressive Disorder, Psychotic Disorders
A United States Study of the Safety and Tolerability of Corlux for Psychotic Symptoms in Psychotic Major Depression
Corlux (mifepristone) is a new medication that modulates the body's use of a hormone called cortisol. Under normal conditions, cortisol and other hormones are created by the body in response to physical and emotional stress…
- Trial name
- NCT00128479
- Testing
- mifepristone, mifepristone 600 mg, mifepristone 1200 mg
- Where
- 44 sites in United States
- Volunteers
- 443 people
- Sponsor
- Corcept Therapeutics
Schizophrenia
A Study of RO4917838 in Participants With Persistent, Predominant Negative Symptoms of Schizophrenia (NN25310)
This multi-center, randomized, double-blind, parallel-group, placebo-controlled study will evaluate the efficacy and safety of RO4917838 in participants with persistent, predominant negative symptoms of schizophrenia.
- Trial name
- NCT01192867
- Testing
- RO4917838, Antipshychotics (Standard of Care)
- Where
- 122 sites in United States, Argentina and 12 more
- Volunteers
- 629 people
- Sponsor
- Hoffmann-La Roche
Schizophrenia
A Study of Long-acting Injectable Risperidone in the Treatment of Patients With Schizophrenia or Schizoaffective Disorder
The purpose of this study is to document the long-term safety and tolerability of risperidone, formulated as a long-acting injectable, in the treatment of patients with schizophrenia or schizoaffective disorder; in addition, to…
- Trial name
- NCT00210691
- Testing
- Risperidone
- Volunteers
- 273 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Schizophrenia
Paliperidone Extended-Release (ER) Versus Risperidone for Neurocognitive Function in Patients With Schizophrenia
Primary objective: To examine whether the switch to paliperidone ER from risperidone improves cognitive function in stabilized patients with schizophrenia.
- Trial name
- NCT00827840
- Testing
- Paliperidone ER, Risperidone
- Where
- South Korea
- Volunteers
- 58 people
- Sponsor
- Chonnam National University Hospital
Schizophrenia
Quetiapine Related Neurochemical Changes as Measured by Magnetic Resonance Spectroscopy in Schizophrenia
we aim to examine whether a representative atypical antipsychotic, quetiapine, has different effects from conventional antipsychotics on the magnetic resonance spectroscopy (MRS) markers in schizophrenia patients.
- Trial name
- NCT00797927
- Testing
- quetiapine, no intervention
- Where
- Taiwan
- Volunteers
- 30 people
- Sponsor
- National Taiwan University Hospital
Schizophrenia
Coaching Intervention for Patients With Early Psychosis
Jockey Club Early Psychosis (JCEP) project is a territory-wide specialized EI service that is launched in August 2009 and provides 3-year phase-specific intervention for adult patients presenting with first-episode psychosis…
- Trial name
- NCT01792856
- Testing
- Recovery-oriented intervention, psychoeducation
- Where
- China
- Volunteers
- 140 people
- Sponsor
- The University of Hong Kong
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.